Trial comparisons

curl "https://conductscience.org/api/comparisons/v1?page=228"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=228

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01332968-deaths",
        "title": "Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: deaths from any cause",
        "summary": "111 of 692 against 104 of 698; risk difference 1.1 points, 95% interval -2.7 to 5.0; NCT01332968, A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)",
        "record": "/library/comparisons/NCT01332968-deaths",
        "nct_id": "NCT01332968",
        "kind": "deaths",
        "participants": 1390,
        "risk_difference": {
          "value": 0.011407489606969523,
          "lower": -0.026683459501813833,
          "upper": 0.04952435676209268
        },
        "group_1": "111 of 692",
        "group_2": "104 of 698",
        "difference": "1.1 points",
        "interval": "-2.7 to 5.0",
        "trial_title": "A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)"
      },
      {
        "id": "NCT01332968-sae",
        "title": "Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events",
        "summary": "309 of 692 against 361 of 698; risk difference -7.1 points, 95% interval -12.3 to -1.8; NCT01332968, A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)",
        "record": "/library/comparisons/NCT01332968-sae",
        "nct_id": "NCT01332968",
        "kind": "serious-adverse-events",
        "participants": 1390,
        "risk_difference": {
          "value": -0.0706601851698494,
          "lower": -0.12264601052400159,
          "upper": -0.01812396318679587
        },
        "group_1": "309 of 692",
        "group_2": "361 of 698",
        "difference": "-7.1 points",
        "interval": "-12.3 to -1.8",
        "trial_title": "A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=229",
  "request_id": "_I38tFJ3ibXPodBn"
}